ArticleMolecular biomedicine2024

Proteogenomics identifies c-Met inhibition as a therapeutic strategy for BAP1-deficient clear cell renal cell carcinoma.

Bowen Du et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.